Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 6/20 | 0.63 |
| ▸ | CDK2 | P24941 | 4/20 | 0.62 |
| ▸ | JAK2 | O60674 | 3/20 | 0.62 |
| ▸ | JAK1 | P23458 | 3/20 | 0.62 |
| ▸ | CDK1 | P06493 | 3/20 | 0.62 |
| ▸ | CDK7 | P50613 | 3/20 | 0.62 |
| ▸ | EGFR | P00533 | 3/20 | 0.62 |
| ▸ | FLT3 | P36888 | 3/20 | 0.62 |
| ▸ | BTK | Q06187 | 3/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.62 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.62 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.62 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.62 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.62 |
| ▸ | JAK3 | P52333 | 2/20 | 0.62 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.62 |
| ▸ | CDC7 | O00311 | 1/20 | 0.62 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.62 |
| ▸ | PLK4 | O00444 | 1/20 | 0.62 |
| ▸ | STK25 | O00506 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2566715 | 0.91 | SYK (0.64) | SYKCDK2JAK2JAK1CDK1 | |
| SCHEMBL2524410 | 0.91 | SYK (0.63) | SYKCDK2JAK2JAK1CDK1 | |
| SCHEMBL2570110 | 0.90 | SYK (0.64) | SYKCDK2JAK2JAK1CDK1 | |
| SCHEMBL2565258 | 0.88 | SYK (0.64) | SYKCDK2JAK2JAK1CDK1 | |
| SCHEMBL14481819 | 0.87 | CTSC (0.53) | SYKCDK2JAK2JAK1CDK1 | |
| SCHEMBL13268031 | 0.87 | CTSC (0.53) | SYKCDK2JAK2JAK1CDK1 | |
| SCHEMBL2564348 | 0.87 | SYK (0.64) | SYKCDK2JAK2JAK1CDK1 | |
| Hydrochloric Acid SCHEMBL15388424 | 0.86 | SYK (0.63) | SYKCDK2JAK2JAK1CDK1 | |
| SCHEMBL2525313 | 0.86 | SYK (0.61) | SYKCDK2JAK2JAK1CDK1 | |
| SCHEMBL3234146 | 0.84 | SYK (0.59) | SYKCDK2JAK2JAK1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518937-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | claimed |
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | claimed |
| US-8278299-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | claimed |
| EP-2382210-A2 | PYRIMIDINEDIAMINE KINASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2011-11-02 | — | — | EP | claimed |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | claimed |
| WO-2010078369-A2 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | claimed |
| US-9040527-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040527-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040527-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20130309228-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130309228-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8518937-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518937-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-8278299-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278299-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278299-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | SYK 2106/4885CDK2 19/4885JAK2 854/4885 |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | SYK 2304/4885CDK2 18/4885JAK2 994/4885 |
| US-20130309228-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | SYK 2106/4885CDK2 19/4885JAK2 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.